Phenylbutyrate-induced apoptosis and differential expression of Bcl-2, Bax, p53 and Fas in human prostate cancer cell lines

Analytical and Quantitative Cytology and Histology

Volumn 22, Issue 1, 2000, Pages 45-54

  Ng, Angela Y ^a   Bales, Wes ^a   Veltri, Robert W ^a  

^a UroCor Incorporated   (United States)

Author keywords

Apoptosis; Phenylbutyrates; Prostate cancer

Indexed keywords

ANDROGEN; ARYLBUTYRIC ACID DERIVATIVE; FAS ANTIGEN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CELL STIMULATION; CYTOSTASIS; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION;

ANDROGENS; ANNEXIN A5; ANTIGENS, CD95; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BIOLOGICAL MARKERS; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION; HUMANS; IN SITU NICK-END LABELING; MALE; PHENYLBUTYRATES; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0033952961     PISSN: 08846812     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Rubenstein R, Zeitlin P: A pilot clinical trial of oral sodium 4-phenylbutyrate (Buphenyl) in deltaF508-homozygous cystic fibrosis patients: Partial restoration of nasal epithelial CFTR function. Am J Respir Crit Care Med 1998;157:484-490
2. Maestri N, Brusilow S, Clissold D, Bassett S: Long-term treatment of girls with ornithine transcarbamylase deficiency. N Engl J Med 1996;335:855-859
3. Faller D, Perrine S: Butyrate in the treatment of sickle cell disease and beta-thalassemia. Curr Opin Hematol 1995;2: 109-117
4. Wood C, Lee C, Grayhack J, Kozlowski J: Phenylacetate and phenylbutyrate promote cellular differentiation in human prostate cancer systems (abstr). Proc Am Assoc Cancer Res 1994;35:A2404
5. Figg W, Walls R, Cooper M, Thibault A, Sartor O, McCall N, Myers C, Samid D: In vitro antitumor effect of hydroxyurea on hormone-refractory prostate cancer cells and its potentiation by phenylbutyrate. Anticancer Drugs 1994;5:336-342
6. Carducci M, Nelson J, Chan-Tack K, Ayyagari S, Sweatt W, Campbell P, Nelson W, Simons J: Phenylbutyrate induces apoptosis in human prostate cancer and is more potent than phenylacetate. Clin Cancer Res 1996;2:379-387
7. Candido E, Reeves R, Davie J: Sodium butyrate inhibits histone deacetylation in cultured cells. Cell 1978;14:105-113
8. D'Anna J, Tobey R, Gurley L: Concentration-dependent effects of sodium butyrate in Chinese hamster cells: Cell-cycle progression, inner-histone acetylation, histone H1 dephosphorylation, and induction of an H1-like protein. Biochemistry 1980;19:2656-2671
9. Wintersberger E, Mudrak I, Wintersberger U: Butyrate inhibits mouse fibroblasts at a control point in the G1 phase. J Cell Biochem 1983;21:239-247
10. Vaziri C, Stice L, Fallar D: Butyrate-induced G1 arrest results from p21-independent disruption of retinoblastoma protein-mediated signals. Cell Growth Differ 1998;9:465-474
11. Soldatenkov V, Prasad S, Voloshin Y, Dritschilo A: Sodium butyrate induces apoptosis and accumulation of ubiquitinated proteins in human breast carcinoma cells. Cell Death Differ 1998;5:307-312
12. Nakano K, Mizuno T, Sowa Y, Orita T, Yoshino T, Okuyama Y, Fujita T, Ohtani-Fujita N, Matsukawa Y, Tokino T, Yamagishi H, Oka T, Nomura H, Sakai T: Butyrate activates the WAF1 /Cip1 gene promoter through Sp1 sites in a p53-negative human colon cancer cell line. J Biochem 1997;272: 22199-22206
13. Danesi R, Figg WER, Myers C: Paclitaxel (Taxol) inhibits protein isoprenylation and induces apoptosis in PC-3 human prostate cancer cells. Mol Pharmacol 1995;47:1106-1111
14. Thalmann G, Anezinis P, Chang S, Zhan H, Kim E, Pathak S, von Eschenbach A, Chung L: Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res 1994;54: 2577-2581
15. Wu H, Heieh J, Gleave M, Brown N, Pathak S, Chung L: Derivation of androgen-independent human LNCaP prostate cancer cell sublines: Roles of bone stromal cells. Int J Cancer 1994;57:406-412
16. Hague A, Manning A, Hanlon K, Huschtscha L, Hart K, Paraskeva C: Sodium butyrate induces apoptosis in human colonic tumour cell lines in a p53-indepenent pathway: Implications for the possible role of dietary fibre in the prevention of large-bowel cancer. Int J Cancer 1993;55:498-505
17. Ng Y, Bales WEB, Wyllie M, Veltri R: Cardura induced apoptosis in prostate cancer cells in vitro. Proc Am Assoc Cancer Res 1997;38:92
18. Ng A, Bales W, Box E, Pickens C, Veltri R: Bcl-2 and Bax but not p53 and Fas are associated with apoptosis induced by phenylbutyrate in prostate cancer cells in vitro. Proc Am Assoc Cancer Res 1998;39:571
19. van Engeland M, Ramaekers FC, Schutte B, Reutelingsperger CP: A novel assay to measure loss of plasma membrane asymmetry during apoptosis of adherent cells in culture. Cytometry 1996;24:131-139
20. Raffo A, Perlman H, Chen M, Day M, Streitman J, Buttyan R: Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res 1995;55:4438-4445
21. Berchem G, Bosseler M, Sugars L, Voeller H, Zeitlin S, Gelmann E: Androgens induce resistance to bcl-2-mediated apoptosis in LNCaP prostate cancer cells. Cancer Res 1995; 55:735-738
22. Campbell M, Dawson M, Koeffler H: Growth inhibition of DU-145 prostate cancer cells by a Bcl-2 antisense oligonucleotide is enhanced by N-(2-hydroxyphenyl)all-trans retinamide. Br J Cancer 1998;77:739-744
23. McDonnell T, Troncoso P, Brisbay S, Logothetis C, Chung L, Hsieh J, Tu S, Campbell M: Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992;52: 6940-6944
24. Kamesaki S, Kamesaki H, Jorgensen T, Tanizawa A, Pommier Y, Cossman J: Bcl-2 protein inhibits etoposide-induced apoptosis through its effects on events subsequent to topoisomerase II-induced DNA strand breaks and their repair. Cancer Res 1993;53:4251-4256
25. Reed J: Regulation of apoptosis by bcl-2 family proteins and its role in cancer and chemoresistance. Curr Opin Oncol 1995;7:541-546
26. Colombel M, Symmans F, Gil S, O'Toole K, Chopin D, Benson M, Olsson C, Korsmeyer S, Buttyan R: Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers. Am J Pathol 1993;143: 390-400
27. McConkey D, Greene G, Pettaway C: Apoptosis resistance increases with metastatic potential in cells of the human LNCaP prostate carcinoma line. Cancer Res 1996;56:5594-5599
28. Krajewska M, Krajewski S, Epstein J, Shabaik A, Sauvageot J, Song K, Kitada S, Reed J: Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am J Pathol 1996;148:1567-1576
29. Kyprianou N, King E, Bradbury D, Rhee J: Bcl-2 overexpression delays radiation-induced apoptosis without affecting the clonogenic survival of human prostate cancer cells. Int J Cancer 1997;70:341-348
30. Cardillo M, Berchem G, Tarkington M, Krajewski S, Krajewski M, Reed J, Tehan T, Ortega L, Lagc J, Gelmann E: Resistance to apoptosis and up regulation of Bcl-2 in benign prostatic hyperplasia after androgen deprivation. J Urol 1997; 158:212-216
31. Beduschi M, Beduschi R, Oesterling J: Alpha-blockade therapy for benign prostate hyperplasia: From a nonselective to a more selective alpha 1A-adrenergic antagonist. Urology 1998;51:861-872
32. Wood C, Sensibar J, Lee C, Kozlowski J: Phenylacetate and phenylbutyrate promote cellular differentiation through downregulation of androgen receptor and bcl-2 levels in the prostate cancer cell line LNCaP (abstr). Proc Am Assoc Cancer Res 1995;36:A3831
33. Thompson C: Apoptosis in the pathogenesis and treatment of diseases. Science 1995;267:1456-1462
34. Korsmeyer S, Shutter J, Veis D, Merry D, Oltvai Z: Bcl-2/Bax: A rheostat that regulates an anti-oxidant pathway and cell death. Semin Cancer Biol 1993;4:327-332
35. Chresta C, Masters J, Hickman J: Hypersensitivity of human testicular tumors to etoposide-induced apoptosis associated with functional p53 and high Bax:Bcl2 ratio. Cancer Res 1996; 56:1834-1841
36. Oltvai Z, Milliman C, Korsmeyer S: Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993;74:609-619
37. Ouyang H, Furukawa T, Abe T, Kato Y, Horii A: The BAX gene, the promoter of apoptosis, is mutated in genetically unstable cancers of the colorectum, stomach, and endometrium. Clinical Cancer Res 1998;4:1071-1074
38. Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima S, Sameshima M, Hase A, Seto Y, Nagata S: The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991;66:233-243
39. Suda T, Nagata S: Purification and characterization of the Fas ligand that induces apoptosis. J Exp Med 1994;179: 873-878
40. Rokhlin O, Bishop G, Hostager B, Waldschmidt T, Sidorenko S, Pavloff N, Kiefer M, Umansky S, Glover R, Cohen M: Fas-mediated apoptosis in human prostatic carcinoma cell lines. Cancer Res 1997;57:1758-1768
41. Kimura K, Yamamoto M: Rapid induction of Fas antigen mRNA expression in vivo by cycloheximide. Cell Biochem Funct 1997;15:81-86
42. Suzuki A, Matsuzawa A, Iguchi T: Down regulation of Bcl-2 is the first step in Fas-mediated apoptosis of male reproductive tract. Oncogene 1996;13:31-37
43. Goillot E, Raingeaud J, Ranger A, Tepper R, Davis R, Harlow E, Sanchez I: Mitogen-activated protein kinase-mediated Fas apoptotic signaling pathway. Proc Natl Acad Sci USA 1997;94:3302-3307
44. Carroll A, Voeller H, Sugars L, Gelmann E: p53 Oncogene mutations in three human prostate cancer cell lines. Prostate 1993;23:123-134
45. Berges RR, Furuya Y, Remington L, English HF, Jacks T, Isaacs JT: Cell proliferation, DNA repair, and p53 function are not required for programmed death of prostatic glandular cells induced by androgen ablation. Proc Natl Acad Sci USA 1993;90:8910-8914
46. Borner M, Myers C, Sartor O, Sei Y, Toko T, Trepel J, Schneider E: Drug-induced apoptosis is not necessarily dependent on macromolecular synthesis or proliferation in the p53-negative human prostate cancer cell line PC-3. Cancer Res 1995; 55:2122-2128
47. Huang A, Candour Edwards R, Rosenthal S, Siders D, Deitch A, White R: p53 And bcl-2 immunohistochemical alterations in prostate cancer treated with radiation therapy. Urology 1998;51:346-351